<DOC>
	<DOCNO>NCT00934479</DOCNO>
	<brief_summary>The purpose study determine whether bacteria normally present bowel different people constipation see effect treatment Food Drug Administration ( FDA ) - approve drug , lubiprostone , bacteria .</brief_summary>
	<brief_title>Intestinal Microecology Chronic Constipation</brief_title>
	<detailed_description>Chronic constipation common condition heterogeneous pathophysiology result clinical manifestation . Recent evidence literature collect laboratory confirm difference gut microbiota healthy individual variety disorder ( e.g. , inflammatory bowel disease , irritable bowel syndrome obesity ) suggest development certain disorder may determine composition gut microbiota . Existing evidence warrant investigation role microbial ecology human gut constipation exploration modification gut microbiota mean treat constipation action colonic metabolism nutrient substrate alter colonic transit fluid flux . The propose research exploit proven capability use high-throughput molecular genomic technique define intestinal microbiome order help define role gut microbiota chronic constipation explore potential value alter microbiota management strategy constipation . The linkage high-throughput genomic analysis cause-and-effect understanding gut microbiota affect bowel function may lead reliable mean manage gut microbiota intent prevent and/or treat constipation . The immediate goal project expand exist information microbial ecology human intestine focus relationship constipation use molecular microbiological technique assess effect gut microorganism result use FDA-approved medication , lubiprostone . Lubiprostone member novel therapeutic class call prostones orally active , bicyclic fatty acid selectively act type 2 chloride channel stimulate chloride secretion induces net increase luminal fluid secretion . Unlike antibiotic , probiotic prebiotic agent , know direct effect gut microbiota . It FDA-approved treatment chronic constipation men woman woman constipation-predominant IBS ( C-IBS ) . The rationale use lubiprostone modify gut microbiota stem use similar strategy control recalcitrant small intestinal bacterial overgrowth ( i.e. , alter fluid flux gut lumen ) . We believe research greatly improve understand role gut microbiota play development constipation potentially lead new strategy combat common problem .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>Inclusion Criteria Healthy Subjects : 1 . Fewer 3 bowel movements/day 3 bowel movements/week without need significant strain defecation frequent sensation incomplete evacuation defecation 2 . Absence current chronic gastrointestinal symptom Inclusion Criteria Chronic Constipation Subjects : 1 . Meet Rome III criterion chronic functional constipation 2 . Colonoscopy within previous 10 year subject ≥ 50 year age Inclusion Criteria ConstipationPredominant IBS Patients : 1 . Meet Rome III criterion CIBS 2 . Colonoscopy within previous 10 year subject ≥ 50 year age 1 . Prior gastrointestinal surgery alter anatomy esophagus , stomach , small/large intestine ( exception include appendectomy cholecystectomy ) 2 . Gastrointestinal , cardiovascular , endocrine , renal , chronic disease likely affect gastrointestinal motility ( e.g. , uncontrolled diabetes mellitus ) 3 . Females childbearing age practice birth control and/or pregnant lactating ( urine pregnancy test perform female subject prior lubiprostone use ) 4 . Significant untreated psychiatric disease 5 . History hypersensitivity reaction intolerance lubiprostone 6 . Inability stop antibiotic , probiotic , fiber supplement 1 month prior stool sample collection 7 . Inability stop proton pump inhibitor , histamine 2 receptor antagonist , prokinetic agent , narcotic analgesic agent , laxative , anticholinergic agent 2 week prior stool sample collection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Chronic Constipation</keyword>
	<keyword>Constipation Predominant Irritable Bowel Syndrome</keyword>
	<keyword>Intestinal Microecology</keyword>
</DOC>